D. Barranco, Alejandra Spinelli, Virginia Beneditto
{"title":"他法米德在乌拉圭首次用于TTR心脏淀粉样变","authors":"D. Barranco, Alejandra Spinelli, Virginia Beneditto","doi":"10.29277/cardio.37.1.12","DOIUrl":null,"url":null,"abstract":"Cardiac amyloidosis is an entity on increasing recognition, transthyretin variety is the most diagnosed in the third age. There is a recent availability of drugs that can improve the prognosis and quality of life of these patients. We present a case of transthyretin amyloidosis and the first use of tafamidis in our country.","PeriodicalId":191575,"journal":{"name":"Revista Uruguaya de Cardiología","volume":"387 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Primer uso de tafamidis en amiloidosis cardíaca TTR en Uruguay\",\"authors\":\"D. Barranco, Alejandra Spinelli, Virginia Beneditto\",\"doi\":\"10.29277/cardio.37.1.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiac amyloidosis is an entity on increasing recognition, transthyretin variety is the most diagnosed in the third age. There is a recent availability of drugs that can improve the prognosis and quality of life of these patients. We present a case of transthyretin amyloidosis and the first use of tafamidis in our country.\",\"PeriodicalId\":191575,\"journal\":{\"name\":\"Revista Uruguaya de Cardiología\",\"volume\":\"387 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Uruguaya de Cardiología\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29277/cardio.37.1.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Uruguaya de Cardiología","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29277/cardio.37.1.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Primer uso de tafamidis en amiloidosis cardíaca TTR en Uruguay
Cardiac amyloidosis is an entity on increasing recognition, transthyretin variety is the most diagnosed in the third age. There is a recent availability of drugs that can improve the prognosis and quality of life of these patients. We present a case of transthyretin amyloidosis and the first use of tafamidis in our country.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
